The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates-Reference-Cited by-同舟云学术

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates

Published:2011-06-26 Issue:1 Volume:69 Page:247-252
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Marcus Leigh,Murphy Robert,Fox Elizabeth,McCully Cynthia,Cruz Raphael,Warren Katherine E.,Meyer Thorsten,McNiff Edward,Balis Frank M.,Widemann Brigitte C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-011-1659-z.pdf

Reference38 articles.

1. Pallis AG et al (2010) Treatment of small-cell lung cancer in elderly patients. Cancer 116(5):1192–1200

2. Steer CB (2009) Chemotherapy for ovarian cancer in the older adult. Curr Treat Options Oncol 10(3–4):159–170

3. Braun AH et al (2004) New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100(8):1558–1577

4. Huncharek M, Kupelnick B, Bishop D (1998) Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 24(5):307–316

5. Fouladi M et al (2006) Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 107(9):2291–2297

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies;Anticancer Research;2022-03-28

2. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors;Pediatric Blood & Cancer;2015-01-03

3. Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib;Current Drug Targets;2014-12-16